The innate immune system is the oldest and most evolutionary part of the immune response,” said Dr. Santosha Vardhana medical associate professor and junior doctor at Memorial Sloan Kettering Cancer Center in New York. For vaccine manufacturers, it will be valuable information to find out what the minimum immune response is for naturally infected people to fight the infection,” said Dr. Wabret. “The majority of those infected – 90% of people – produce antibodies,” says Dr. Joel Ernst, an immunology specialist, professor of medicine and head of the Department of Experimental Medicine at the UCSF School of Medicine. It will be important to monitor the immune response to the vaccine, especially in older people and others most susceptible to serious infections,” says Dr. Ernst. In a recent study, scientists at the Institute of Immunology of La Yolla and others found that the immune system should use a stratified, viral approach to controlling the severity of infection. “Its adaptive immune response is much more specific. “When your adaptive immune system intervenes, some types of leukocytes or lymphocytes activate the defense. The researchers found that the way human T cells react to VID-19 infection varies greatly, Ernst explains. People infected with VID-19, but without symptoms, have less resistant antibodies that may not be detected, Ernst explains. In this study, the researchers took blood samples from 50 VID-19 patients and tested them for specific antibodies to coronavirus, auxiliary T cells and lethal T cells. The B cells produce antibodies that bind to a specific antigen or invasive protein and help destroy immune cells. “One thing we still do not know is the minimal immune response needed to prevent infection. “This is important for vaccine development. According to researchers from La Yoll, T cells may be more important in fighting the “natural” SARS CoV-2 infection, while antibodies may be more important in the vaccine. In general, vaccines currently under development provide a neutralizing response to antibodies, although some are reported to have a response to the T-cells, Ernst said. The results may explain why people over 65, who are more likely to have a weaker T-cell response, are at greater risk of serious infection or death, the researchers say. Another recent study found that people with severe VOCID-19 cases produced antibodies up to four months after symptoms appeared. They compared blood samples of survivors with blood samples from 66 contacts and 23 negative controls and found that many survivors were able to fight repeated infection even without antibodies because they were able to produce T cells.